文献速递青光眼

英国青光眼治疗研究中眼压波动与视野进展速率的关系

Relationship between Intraocular Pressure Fluctuation and Visual Field Progression Rates in the United Kingdom Glaucoma Treatment Study.
PubMed 文献 · Ophthalmology · 2024-02-13

该随机双盲安慰剂对照多中心试验纳入213例安慰剂组和217例治疗组受试者,评估眼压波动指标与视野进展速率的关系。安慰剂组中仅主成分1与平均偏差进展速率显著相关,标准化眼压波动指标均无显著关联;治疗组中无变量与平均偏差速率显著相关。结论认为无证据支持日间或长期眼压波动是青光眼进展的独立因素。

要点

  • 安慰剂组中仅主成分1与平均偏差进展速率显著相关(估计值-0.19 dB/年,P<0.001)。
  • 安慰剂组最快5个位点进展速率与主成分1、中央角膜厚度和标准化眼动脉搏动振幅相关。
  • 治疗组中仅主成分1与最快5个位点进展速率相关(估计值-0.27 dB/年,P=0.028)。

核心结论

  • 无证据支持临床实践中测量的日间或长期眼压波动是青光眼进展的独立因素;眼压的其他方面(包括平均眼压和峰值眼压)可能更具信息价值。
  • 眼动脉搏动振幅可能是青光眼进展较快的独立因素。

研究设计与样本

  • 随机、双盲、安慰剂对照多中心试验。
  • 纳入至少有5次视野检查的受试者,安慰剂组213例,治疗组217例。
  • 采用线性混合模型评估眼压指标与视野进展速率(平均偏差和最快5个位点)的关联。

主要发现

  • 安慰剂组中仅主成分1与平均偏差进展速率显著相关(估计值-0.19 dB/年,标准误0.04 dB/年;P<0.001),标准化眼压波动指标均无显著关联。
  • 治疗组中无变量与平均偏差进展速率显著相关。
  • 安慰剂组最快5个位点进展速率与主成分1(估计值-0.58 dB/年,标准误0.16 dB/年;P<0.001)、中央角膜厚度(每增厚10 μm估计值0.26 dB/年,标准误0.10 dB/年;P=0.01)和标准化眼动脉搏动振幅(估计值-3.50 dB/年,标准误1.04 dB/年;P=0.001)相关;标准化日间和长期眼压波动无显著关联。
  • 治疗组中仅主成分1与最快5个位点进展速率相关(估计值-0.27 dB/年,标准误0.12 dB/年;P=0.028)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To investigate whether intraocular pressure (IOP) fluctuation is associated independently with the rate of visual field (VF) progression in the United Kingdom Glaucoma Treatment Study. DESIGN: Randomized, double-masked, placebo-controlled multicenter trial. PARTICIPANTS: Participants with ≥5 VFs (213 placebo, 217 treatment). METHODS: Associations between IOP metrics and VF progression rates (mean deviation [MD] and five fastest locations) were assessed with linear mixed models. Fluctuation variables were mean Pascal ocular pulse amplitude (OPA), standard deviation (SD) of diurnal Goldmann IOP (diurnal fluctuation), and SD of Goldmann IOP at all visits (long-term fluctuation). Fluctuation values were normalized for mean IOP to make them independent from the mean IOP. Correlated nonfluctuation IOP metrics (baseline, peak, mean, supine, and peak phasing IOP) were combined with principal component analysis, and principal component 1 (PC1) was included as a covariate. Interactions between covariates and time from baseline modeled the effect of the variables on VF rates. Analyses were conducted separately in the two treatment arms. MAIN OUTCOME MEASURES: Associations between IOP fluctuation metrics and rates of MD and the five fastest test locations. RESULTS: In the placebo arm, only PC1 was associated significantly with the MD rate (estimate, -0.19 dB/year [standard error (SE), 0.04 dB/year]; P < 0.001), whereas normalized IOP fluctuation metrics were not. No variable was associated significantly with MD rates in the treatment arm. For the fastest five locations in the placebo group, PC1 (estimate, -0.58 dB/year [SE, 0.16 dB/year]; P < 0.001), central corneal thickness (estimate, 0.26 dB/year [SE, 0.10 dB/year] for 10 μm thicker; P = 0.01) and normalized OPA (estimate, -3.50 dB/year [SE, 1.04 dB/year]; P = 0.001) were associated with rates of progression; normalized diurnal and long-term IOP fluctuations were not. In the treatment group, only PC1 (estimate, -0.27 dB/year [SE, 0.12 dB/year]; P = 0.028) was associated with the rates of progression. CONCLUSIONS: No evidence supports that either diurnal or long-term IOP fluctuation, as measured in clinical practice, are independent factors for glaucoma progression; other aspects of IOP, including mean IOP and peak IOP, may be more informative. Ocular pulse amplitude may be an independent factor for faster glaucoma progression. FINANCIAL DISCLOSURE(S): Proprietary or commercial disclosure may be found in the Footnotes and Disclosures at the end of this article.

来源:Ophthalmology,查看原文。版权归原作者所有。

引用

  1. Rabiolo A, Montesano G, Crabb DP, et al. Relationship between Intraocular Pressure Fluctuation and Visual Field Progression Rates in the United Kingdom Glaucoma Treatment Study. Ophthalmology. 2024. PMID: 38354911. doi:10.1016/j.ophtha.2024.02.008

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。